Prati
Jonathan Pol
Jonathan Pol
INSERM, Centre de Recherche des Cordeliers (Paris), Gustave Roussy Cancer Campus (Villejuif)
Potvrđena adresa e-pošte na inserm.fr
Naslov
Citirano
Citirano
Godina
Consensus guidelines for the detection of immunogenic cell death
O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ...
Oncoimmunology 3 (9), e955691, 2014
8492014
Caloric restriction mimetics enhance anticancer immunosurveillance
F Pietrocola, J Pol, E Vacchelli, S Rao, DP Enot, EE Baracco, S Levesque, ...
Cancer cell 30 (1), 147-160, 2016
5162016
First oncolytic virus approved for melanoma immunotherapy
J Pol, G Kroemer, L Galluzzi
Oncoimmunology 5 (1), e1115641, 2016
3622016
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
J Pol, E Vacchelli, F Aranda, F Castoldi, A Eggermont, I Cremer, ...
Oncoimmunology 4 (4), e1008866, 2015
3072015
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
P Liu, L Zhao, J Pol, S Levesque, A Petrazzuolo, C Pfirschke, C Engblom, ...
Nature communications 10 (1), 1486, 2019
2462019
The molecular hallmarks of the serrated pathway in colorectal cancer
FDE De Palma, V D’argenio, J Pol, G Kroemer, MC Maiuri, F Salvatore
Cancers 11 (7), 1017, 2019
2182019
Maraba virus as a potent oncolytic vaccine vector
JG Pol, L Zhang, BW Bridle, KB Stephenson, J Rességuier, S Hanson, ...
Molecular therapy 22 (2), 420-429, 2014
1952014
Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies
S Gujar, JG Pol, Y Kim, PW Lee, G Kroemer
Trends in immunology 39 (3), 209-221, 2018
1882018
Trial watch: peptide-based vaccines in anticancer therapy
L Bezu, O Kepp, G Cerrato, J Pol, J Fucikova, R Spisek, L Zitvogel, ...
Oncoimmunology 7 (12), e1511506, 2018
1662018
Trial watch: Oncolytic viruses for cancer therapy
J Pol, N Bloy, F Obrist, A Eggermont, J Galon, I Cremer, P Erbs, ...
Oncoimmunology 3 (6), e28694, 2014
1572014
Effects of interleukin-2 in immunostimulation and immunosuppression
JG Pol, P Caudana, J Paillet, E Piaggio, G Kroemer
The Journal of Experimental Medicine 217 (1), 2020
1532020
Trial Watch—Oncolytic viruses and cancer therapy
J Pol, A Buqué, F Aranda, N Bloy, I Cremer, A Eggermont, P Erbs, ...
Oncoimmunology 5 (2), e1117740, 2016
1442016
Trial Watch: Peptide-based anticancer vaccines
J Pol, N Bloy, A Buqué, A Eggermont, I Cremer, C Sautes-Fridman, ...
Oncoimmunology 4 (4), e974411, 2015
1432015
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy
BW Bridle, L Chen, CG Lemay, JS Diallo, J Pol, A Nguyen, A Capretta, ...
Molecular Therapy 21 (4), 887-94, 2013
1292013
Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy
ST Workenhe, G Simmons, JG Pol, BD Lichty, WP Halford, KL Mossman
Molecular Therapy 22 (1), 123-131, 2014
1282014
Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
S Gujar, JG Pol, G Kroemer
OncoImmunology, e1442169, 2018
1232018
Metabolic vulnerability of cisplatin‐resistant cancers
F Obrist, J Michels, S Durand, A Chery, J Pol, S Levesque, A Joseph, ...
The EMBO journal 37 (14), e98597, 2018
1002018
Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance
N Bloy, P Garcia, CM Laumont, JM Pitt, A Sistigu, G Stoll, T Yamazaki, ...
Immunological reviews 280 (1), 165-174, 2017
992017
Acyl-CoA-binding protein is a lipogenic factor that triggers food intake and obesity
JM Bravo-San Pedro, V Sica, I Martins, J Pol, F Loos, MC Maiuri, ...
Cell Metabolism 30 (4), 754-767. e9, 2019
942019
Metabolic effects of fasting on human and mouse blood in vivo
F Pietrocola, Y Demont, F Castoldi, D Enot, S Durand, M Semeraro, ...
Autophagy 13 (3), 567-578, 2017
892017
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20